Because they have yet to pass national legislation protecting the chiropractic profession, Japanese DCs are in a similar situation that U.S. DCs faced. We were fortunate enough to be able to pass chiropractic licensure state by state. The DCs in Japan must accomplish this nationally, which has proved to be an extremely difficult task. And in spite of their efforts, Japanese DCs are currently faced with two chiropractic professions.
Chondroitin, Glucosamine and Prevention of Joint-Space Loss
In the fall of 2008, a paper was published reporting on an extension of the Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT), a study I summarized several years ago in Dynamic Chiropractic.1,2 In the extension portion of the trial, approximately one-third (572) of the original 1,583 subjects continued to take one of five treatments for an additional two years: glucosamine, 1,500 mg/day; chondroitin, 1,200 mg/day; glucosamine (1,500 mg) and chondroitin (1,200 mg); Celebrex, 200 mg/day; or placebo. Knee joint space was measured radiographically at baseline, 12 and 24 months. The mean two-year loss in joint space, with adjustment for diseases and other risk factors, for each of the five study groups was as follows (listed in order of increasing joint-space loss):
Follow-Up Results From the Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT) | |
Group | Joint-Space Loss |
Glucosamine | 0.013 mm |
Chondroitin | 0.107 mm |
Celebrex | 0.111 mm |
Placebo | 0.166 mm |
Glucosamine and chondroitin | 0.194 mm |
A few months later, results of another two-year study was published.3 In that study, 622 patients with knee arthritis had randomly received either 800 mg of chondroitin sulfate or a placebo for two years. Radiographic analysis at baseline, 12 and 24 months was performed. After two years, the mean joint-space losses were as follows:
Results From the Study on Osteoarthritis Progression Prevention | |
Group | Joint-Space Loss |
Chondroitin sulfate | 0.070 mm |
Placebo | 0.310 mm |
The authors concluded that the radiographic progression of joint-space loss was reduced in patients who took chondroitin sulfate compared to those who took placebo. The authors also noted that pain was noticeably reduced in the chondroitin group. This conflicted with the conclusions of the GAIT extension, which, according to the authors, were statistically insignificant.
For some people, glucosamine and chondroitin will have varying degrees of benefit. Research has yet to determine who will be a responder, nor can we say if chondroitin, glucosamine or the combination of the two delivers the best results. Until that happens, the best advice we can give to our patients is to take a trial-and-error approach and stick to what works best.
References
- Sawitzke AD, Shi H, Finco MF, et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the Glucosamine/Chondroitin Arthritis Intervention Trial. Arthritis Rheumatol, 2008;58(10):3183-91.
- Andersen GD. "The Glucosamine/Chondroitin Arthritis Intervention Trial." Dynamic Chiropractic, May 8, 2006;24(13):18
- Kahan A, Uebelhart D, DeVathaire F, et al. Long-term effects of chondroitin (4 and 6 sulfate) on knee osteoarthritis: The Study on Osteoarthritis Progression Prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol, 2009;60(2):524-33.